Médicaments anti-TNFα (tumor necrosis factor α) en gynécologie et en obstétrique

0Citations
Citations of this article
1Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Anti-TNFα treatments have modified the medical care, the course and the quality of life of the patients with autoimmune rheumatic, cutaneous or bowel inflammatory diseases. On the other hand, these treatments may have potential severe side effects during pregnancy (congenital malformations, fetal infections). Actually, many pregnancies have been reported during anti-TNFα exposures, with good maternal and neonatal outcomes. The introduction or the discontinuation of these treatments will always have to be discussed with the specialist of the chronic disease and, ideally, during a preconceptional counselling. In gynecology, anti-TNFα drugs may offer a new safe and effective approach to treating patients with recurrent miscarriages or unexplained or failed in vitro fertilization cycles. On the other hand, these treatments significantly increase the risk for serious infections or viral reactivations and may promote gynaecological malignancies. An adapted gynaecological survey is necessary. © 2011 Elsevier Masson SAS. All rights reserved.

Cite

CITATION STYLE

APA

Ducarme, G., Amate, P., Seirafi, M., Ceccaldi, P. F., Bouhnik, Y., & Luton, D. (2011). Médicaments anti-TNFα (tumor necrosis factor α) en gynécologie et en obstétrique. Journal de Gynecologie Obstetrique et Biologie de La Reproduction, 40(6), 492–497. https://doi.org/10.1016/j.jgyn.2011.05.009

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free